A DREAM Challenge to Build Prediction Models for Short-Term Discontinuation of Docetaxel in Metastatic Castration-Resistant Prostate Cancer

PURPOSE: Docetaxel has a demonstrated survival benefit for patients with metastatic castration-resistant prostate cancer (mCRPC); however, 10% to 20% of patients discontinue docetaxel prematurely because of toxicity-induced adverse events, and the management of risk factors for toxicity remains a ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Seyednasrollah, Fatemeh, Koestler, Devin C., Wang, Tao, Piccolo, Stephen R., Vega, Roberto, Greiner, Russell, Fuchs, Christiane, Gofer, Eyal, Kumar, Luke, Wolfinger, Russell D., Kanigel Winner, Kimberly, Bare, Chris, Neto, Elias Chaibub, Yu, Thomas, Shen, Liji, Abdallah, Kald, Norman, Thea, Stolovitzky, Gustavo, Soule, Howard R., Sweeney, Christopher J., Ryan, Charles J., Scher, Howard I., Sartor, Oliver, Elo, Laura L., Zhou, Fang Liz, Guinney, Justin, Costello, James C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2017
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874023/
https://www.ncbi.nlm.nih.gov/pubmed/30657384
http://dx.doi.org/10.1200/CCI.17.00018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874023/
https://www.ncbi.nlm.nih.gov/pubmed/30657384
http://dx.doi.org/10.1200/CCI.17.00018

Ejemplares similares